Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …

Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …

Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell
acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic …

Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of
relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen …

Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat
subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor …

The remarkable success of chimeric antigen receptor (CAR)-engineered T cells in pre-B cell
acute lymphoblastic leukemia (ALL) and B cell lymphoma led to the approval of anti-CD19 …

Chimeric antigen receptor (CAR) T-cell therapy exhibits desirable and robust efficacy in
patients with acute lymphoblastic leukemia (ALL). Stimulated by the revolutionized progress …

Combining synthetic biology with adoptive T-cell transfer has led to promising advances in
the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse …

In recent years, cell-based immunotherapies have demonstrated promising results in the
treatment of cancer. Chimeric antigen receptors (CARs) arm effector cells with a weapon for …

Simple Summary In relapsed, refractory B cell malignancies and multiple myeloma, chimeric
antigen receptor (CAR) T cell therapy has represented a major scientific advancement with …